Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinicopathologic and Immunohistochemical Features of Enfortumab Vedotin-Induced Cutaneous Toxicity.

International journal of dermatology·2026
Same author

Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies.

Blood·2026
Same author

Human papilloma virus infection and mismatch repair protein expression in sebaceous neoplasms of the genital area.

Histopathology·2025
Same author

RB1 inactivation in cutaneous carcinomas.

Histopathology·2025
Same author

Mycoplasma pneumoniae-Induced Rash and Mucositis: Clinicopathologic Characterization of 11 Cases.

Journal of cutaneous pathology·2025
Same author

ALK Expression in Nerve Sheath Myxoma: A Potential Diagnostic Pitfall.

Journal of cutaneous pathology·2025
Same journal

Profile of a Founder: Herbert Zachareus Lund.

Journal of cutaneous pathology·2026
Same journal

The National Resident Match Program Arrives in Dermatopathology: 15 Years of Resilient Advocacy by the American Society of Dermatopathology's Fellowship Training Program Directors' Committee.

Journal of cutaneous pathology·2026
Same journal

Evaluating Large Language Models for Melanocytic Lesion Pathology Report Interpretation.

Journal of cutaneous pathology·2026
Same journal

An Atypical Skin Presentation of Adult-Onset Still's Disease With Histological Description: A Case Report.

Journal of cutaneous pathology·2026
Same journal

Elevated NLRP1 and IL-1β Expression Supports Inflammasome Activation in SJS/TEN.

Journal of cutaneous pathology·2026
Same journal

Diagnostic Utility of PRAME Immunohistochemistry for Distinguishing Acral Melanoma From Acral Melanocytic Nevi.

Journal of cutaneous pathology·2026
See all related articles

Related Experiment Video

Updated: Jul 27, 2025

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
09:08

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

5.5K

CD30 expression in cutaneous B-cell lymphomas.

Olabisi Afolayan-Oloye1, Lili Zhao2, Trilokraj Tejasvi3

  • 1Department of Pathology, Beaumont Hospital, Royal Oak, Michigan, USA.

Journal of Cutaneous Pathology
|June 8, 2023
PubMed
Summary
This summary is machine-generated.

CD30 expression is found in some cutaneous B-cell lymphomas (CBCLs), particularly primary cutaneous follicle center lymphoma. This expression correlates with favorable clinical features, suggesting potential therapeutic value.

Keywords:
B-cell lymphomaCD30cutaneous

More Related Videos

Murine Model of CD40-activation of B cells
12:24

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

12.7K
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.0K

Related Experiment Videos

Last Updated: Jul 27, 2025

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
09:08

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

5.5K
Murine Model of CD40-activation of B cells
12:24

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

12.7K
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.0K

Area of Science:

  • Dermatology
  • Oncology
  • Pathology

Background:

  • CD30 expression is infrequently documented in cutaneous B-cell lymphomas (CBCLs).
  • Understanding CD30 expression patterns is crucial for accurate diagnosis and prognosis in CBCLs.
  • This study investigates CD30 in various CBCL subtypes and reactive lymphoid hyperplasia (RLH).

Purpose of the Study:

  • To examine CD30 expression in a cohort of CBCL and RLH patients.
  • To correlate CD30 expression with clinicopathologic features of CBCL.
  • To assess the diagnostic and potential therapeutic implications of CD30 in CBCL.

Main Methods:

  • CD30 expression was analyzed in 82 CBCL patients and 10 RLH patients.
  • CBCL subtypes included primary cutaneous follicle center lymphoma (PCFCL), systemic/nodal follicular lymphoma (SFL), primary cutaneous marginal zone lymphoma (PCMZL/LPD), systemic marginal zone lymphoma (SMZL), and primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT).
  • Expression was scored for intensity and extent and correlated with clinical data, including age, sex, PET/CT findings, LDH levels, and bone marrow status.

Main Results:

  • CD30 expression was detected in 35% of CBCL cases, varying in intensity and extent.
  • Expression was most frequent in PCFCL and absent in PCDLBCL-LT.
  • CD30 expression in CBCL was associated with favorable clinical indicators: younger age, negative PET/CT, and normal LDH levels.

Conclusions:

  • CD30 can be expressed in CBCL, potentially leading to diagnostic challenges.
  • PCFCL most commonly exhibits CD30 expression, linked to favorable prognostic factors.
  • Strong and diffuse CD30 expression may represent a therapeutic target in select CBCL cases.